Dailypharm Live Search Close

Lipitor¡¯s sales stay strong for good reason

By Son, Hyung-Min | translator Kim, Jung-Ju

24.04.24 12:15:19

°¡³ª´Ù¶ó 0
Lipitor remains the leading dyslipidemia drug for 20 years since 2003

The drug demonstrated efficacy not only in global studies but also in domestic patients in clinical trials

Lipitor is the only statin indicated for secondary cardiovascular prevention

 ¡ãBill Schuster, Country Manager of Viatris Korea

The dyslipidemia treatment Lipitor has been able to remain the No. 1 selling drug for 20 years, supported by various clinical evidence. Lipitor has proven its efficacy in patients with dyslipidemia not only globally but also domestically. Based on various clinical evidence, major domestic and international societies still recommend statins as the preferred treatment for dyslipidemia.

On April 24, Viatris Korea held a press conference at the Westin Josun Hotel in Seoul to celebrate the 25th anniversary of Lipitor's launch in Korea. Lipitor is the first atorvastatin-based dyslipidemia treatment that had been developed by Warner-Lambert (now Pfizer). Lipitor was approved by the U.S. Food and Drug Administ

Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)